Viagra (Sildenafil) in Children Under 12: Off-Label Use, Evidence, and Clinical Guidance

What Is Sildenafil and Why Is It Used in Young Children?

Sildenafil is a phosphodiesterase type 5 (PDE-5) inhibitor that relaxes smooth muscle in pulmonary blood vessels by preventing the breakdown of cyclic guanosine monophosphate (cGMP). In adults, Viagra is prescribed for erectile dysfunction. In children, the same molecule under the brand name Revatio targets pulmonary arterial hypertension and related vascular conditions.

The PDE-5 Mechanism in Pediatric Pulmonary Vascular Disease

Pulmonary arterial hypertension in children shares many pathophysiological features with adult PAH, including endothelial dysfunction, vascular remodeling, and elevated pulmonary vascular resistance. PDE-5 is highly expressed in pulmonary vascular smooth muscle, and its inhibition by sildenafil produces measurable reductions in mean pulmonary arterial pressure (mPAP) 1.

Neonatal pulmonary vasculature is especially PDE-5-rich. This makes sildenafil pharmacologically rational even in patients born prematurely or at term with persistent pulmonary hypertension of the newborn (PPHN). A 2017 Cochrane review found that sildenafil reduced mortality and improved oxygenation index in neonates with PPHN when inhaled nitric oxide was unavailable 2.

Revatio vs. Viagra: Why the Brand Name Matters

Clinicians and parents sometimes conflate these two products. Viagra (sildenafil 25 mg, 50 mg, 100 mg tablets) carries no pediatric labeling. Revatio (sildenafil 20 mg tablets, 10 mg/12.5 mL oral suspension, 10 mg/12.5 mL IV solution) was approved by the FDA in 2005 for adult PAH and subsequently studied in pediatric populations 3. Off-label use in children under 12 almost always means Revatio formulations, not Viagra tablets.

FDA Regulatory Status for Pediatric Sildenafil

The FDA approved Revatio for adult PAH in 2005. Pediatric labeling information was added based on the STARTS program, but a critical mortality safety communication in 2012 changed prescribing practice significantly.

The 2012 FDA Mortality Warning

In August 2012, the FDA issued a Drug Safety Communication warning that long-term use of high-dose sildenafil (20 mg three times daily or higher by pediatric weight standards) was associated with increased mortality in children aged 1 to 17 with PAH. The warning stated: "FDA recommends against the use of Revatio (sildenafil) for children between 1 and 17 years with pulmonary arterial hypertension" at doses above the low range 4.

This warning does not prohibit prescribing. It advises that physicians carefully weigh the dose-dependent mortality risk documented in STARTS-2 extension data, particularly for children over 20 kg receiving medium or high doses.

STARTS-1 and STARTS-2 Trial Data

The STARTS-1 trial (N=235) was a randomized, double-blind, placebo-controlled study of oral sildenafil in children aged 1 to 17 with PAH. Participants received low (10 mg), medium (20 mg), or high (40 mg) doses three times daily based on weight. At 16 weeks, peak VO2 improved by 7.7% in the combined sildenafil group vs. A decline of 3.4% in placebo (P<0.001) 5.

STARTS-2, the open-label extension, enrolled 234 patients and reported that after a median of 3 years, all-cause mortality was higher in the high-dose group (hazard ratio 3.95 vs. Low dose) 6. This dose-response mortality relationship drove the 2012 FDA warning and remains the central safety concern for any prescriber using sildenafil in this age group.

Off-Label Uses of Sildenafil in Children Under Age 12

Most sildenafil use in children under 12, and especially under 1 year, falls outside any approved label. The three most common off-label contexts are PPHN, bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH), and congenital heart disease-related pulmonary hypertension.

Persistent Pulmonary Hypertension of the Newborn (PPHN)

PPHN occurs when neonatal pulmonary vascular resistance fails to fall after birth, resulting in hypoxemia and right-to-left shunting. Inhaled nitric oxide (iNO) is the first-line therapy, but it is expensive, requires specialized delivery equipment, and is unavailable in many low- and middle-income settings 2.

Sildenafil oral or nasogastric dosing at 0.5 to 2 mg/kg every 6 to 12 hours has been studied in multiple small randomized trials. A 2013 randomized controlled trial published in Pediatrics (N=51) found that oral sildenafil 1 mg/kg every 6 hours produced comparable oxygenation improvement to standard management in settings where iNO was unavailable, with a mean reduction in oxygenation index from 25.3 to 8.9 at 72 hours 7.

Systemic hypotension is the most concerning acute adverse effect in neonates. Blood pressure monitoring every 30 to 60 minutes during dose initiation is standard practice at most centers.

Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension

BPD-PH affects roughly 17 to 25% of very preterm infants surviving to 36 weeks corrected age and carries significant mortality risk. Sildenafil is among the most commonly used pulmonary vasodilators in this population despite no approved label for this indication 8.

The American Heart Association and American Thoracic Society 2015 consensus statement on pediatric pulmonary hypertension acknowledged sildenafil as a reasonable option for BPD-PH while noting the evidence base consisted largely of retrospective cohort data and small prospective studies 9.

Dosing in preterm infants typically starts at 0.5 mg/kg per dose orally every 8 hours, titrating upward based on echocardiographic response. Full clinical benefit on right ventricular pressure can take 4 to 8 weeks to become apparent on serial imaging.

Congenital Heart Disease and Post-Surgical Pulmonary Hypertension

Children with congenital heart defects involving left-to-right shunts, such as large ventricular septal defects or atrioventricular canal defects, can develop pulmonary hypertension from chronic volume and pressure overload. After surgical correction, residual pulmonary hypertension or pulmonary hypertensive crises remain life-threatening.

A prospective observational study of 22 children (mean age 2.4 years) undergoing cardiac surgery found that intravenous sildenafil 0.1 mg/kg over 3 hours significantly reduced pulmonary-to-systemic vascular resistance ratios by a mean of 28% compared to baseline (P<0.05) 10. Post-operative protocols at several major pediatric cardiac centers include oral sildenafil bridging therapy during the vulnerable early post-surgical window.

Dosing Guidance for Children Under 12

No single universally accepted dosing protocol exists for sildenafil in children under 12 across all indications. The FDA-approved Revatio label for PAH uses weight-based tiering, and most off-label neonatal and infant dosing extrapolates from that framework combined with pharmacokinetic data.

Weight-Based Dosing for PAH (Revatio Label, Ages 1 to 17)

The Revatio prescribing information stratifies doses as follows for children with PAH: patients weighing 20 kg or less receive 10 mg three times daily; patients over 20 kg receive 20 mg three times daily. These are the low doses associated with the most favorable safety data from STARTS-1 3. Medium and high doses that were studied in STARTS-2 showed increased mortality and are not recommended by the FDA outside specialized protocols.

Neonatal and Infant Off-Label Dosing

For PPHN in full-term neonates, published protocols range from 0.5 mg/kg to 2 mg/kg per dose every 6 to 12 hours orally or via nasogastric tube. A pharmacokinetic study of 36 neonates published in the British Journal of Clinical Pharmacology found that a loading dose of 3 mg/kg followed by 1 mg/kg every 6 hours achieved target plasma concentrations of 100 to 200 ng/mL in the majority of patients 11.

For BPD-PH in preterm infants, most centers begin at 0.5 mg/kg every 8 hours and titrate to echocardiographic response, rarely exceeding 2 mg/kg every 6 hours. IV sildenafil carries higher hypotension risk in this population and is reserved for patients unable to tolerate enteral feeds.

Monitoring Parameters During Treatment

Clinicians prescribing sildenafil off-label in children under 12 should establish a monitoring plan that includes the following at minimum:

• Baseline and weekly echocardiography for the first month
• Blood pressure measurements before and 1 hour after each dose during initiation
• Pulse oximetry continuously in neonates; spot checks every 4 to 6 hours in older infants
• Liver function tests at baseline and every 3 months (sildenafil is hepatically metabolized via CYP3A4)
• Review of concurrent medications for CYP3A4 inhibitors (fluconazole, clarithromycin) that raise sildenafil exposure

Pharmacokinetics in Young Children

Adult pharmacokinetic data cannot be directly applied to children under 12, particularly neonates, whose CYP3A4 activity is approximately 30 to 40% of mature adult levels at birth and reaches adult levels by 6 to 12 months of age 12.

Absorption and Bioavailability

Oral bioavailability of sildenafil in school-age children averages approximately 40%, consistent with adult data. In neonates, gastrointestinal motility and gastric pH differences may alter absorption, and inter-patient variability is substantial. The oral suspension formulation (10 mg/12.5 mL) is preferred in children who cannot swallow tablets, as it allows precise small-volume dosing.

Metabolism and Half-Life

Sildenafil is primarily metabolized to N-desmethylsildenafil by CYP3A4 and CYP2C9. In preterm neonates, reduced CYP3A4 maturity extends the half-life to 6 to 11 hours, compared to 3 to 5 hours in older children and adults 11. This extended half-life justifies longer dosing intervals in neonates and increases the risk of drug accumulation with standard adult interval schedules.

Safety Profile and Contraindications in Pediatric Patients

The safety concerns in children under 12 differ somewhat from those in adults. Erectile dysfunction-related adverse effects are irrelevant. The dominant safety signals are hemodynamic.

Systemic Hypotension

Sildenafil's PDE-5 inhibition affects systemic vasculature as well as pulmonary vasculature. In neonates and infants with already-low systemic blood pressure, even modest vasodilation can produce clinically significant hypotension. The STARTS-1 trial reported hypotension in 4.4% of sildenafil-treated children vs. 1.7% in placebo 5.

Dose-Dependent Mortality in the STARTS Extension

The most serious safety signal remains the STARTS-2 mortality data. The FDA's 2012 communication specifically noted that after 3 years of follow-up, survival was 94% in the low-dose group, 88% in the medium-dose group, and 84% in the high-dose group 4. Prescribers should document this risk discussion in the medical record.

Absolute Contraindications

Sildenafil is contraindicated with nitrates in any form, including iNO at doses used therapeutically in PPHN. This creates a clinical challenge: if iNO is the preferred therapy, adding sildenafil risks severe systemic hypotension. Most protocols sequence these therapies rather than combining them. Sildenafil is also contraindicated with riociguat (a soluble guanylate cyclase stimulator sometimes used in pediatric PAH centers) 3.

Clinical Guidelines and Specialist Recommendations

Multiple professional society guidelines have addressed sildenafil in pediatric pulmonary hypertension, though none specifically address the Viagra formulation in children under 12.

AHA/ATS 2015 Pediatric Pulmonary Hypertension Guidelines

The American Heart Association and American Thoracic Society 2015 joint scientific statement on pediatric pulmonary hypertension states: "Sildenafil monotherapy may be considered for children with PAH who are at low risk of disease progression, with careful attention to dose and close follow-up." The statement assigns sildenafil a Class IIa, Level B recommendation for idiopathic PAH in children 9.

The same guidelines note that for PPHN in term neonates, sildenafil is a reasonable alternative when iNO is unavailable, based on several small randomized trials and the 2017 Cochrane review 2.

European Pediatric Pulmonary Vascular Disease Network

The European Pediatric Pulmonary Vascular Disease Network 2019 consensus paper supports use of PDE-5 inhibitors in children at specialized centers, recommending low-dose sildenafil as initial oral monotherapy and escalation only under close specialist supervision 13.

Practical Prescribing Considerations

Prescribers outside of quaternary pediatric cardiology or neonatology centers should strongly consider transfer or telemedicine consultation before initiating sildenafil in a child under 12. Off-label prescribing in this context requires documented informed consent discussing the STARTS-2 mortality data, the absence of FDA approval for the specific indication, and the monitoring plan.

Comparing Sildenafil to Other Pediatric Pulmonary Vasodilators

Sildenafil is one of three main oral pulmonary vasodilator classes used in children with PAH. The others are endothelin receptor antagonists (bosentan, ambrisentan, macitentan) and prostanoids (treprostinil, iloprost).

Bosentan has dedicated pediatric dosing down to 3 kg and carries its own hepatotoxicity monitoring requirements. A 2014 Cochrane review found bosentan improved 6-minute walk distance in pediatric PAH but noted limited comparative data against sildenafil 14.

For PPHN specifically, iNO remains the gold standard where available. Sildenafil fills a critical access gap in settings without iNO delivery capability.